Literature DB >> 20143465

Colorectal cancer prognosis twenty years later.

Luis Bujanda1, Cristina Sarasqueta, Elisabeth Hijona, Lander Hijona, Angel Cosme, Ines Gil, Jose Luis Elorza, Jose I Asensio, Santiago Larburu, José M Enríquez-Navascués, Rodrigo Jover, Francesc Balaguer, Xavier Llor, Xavier Bessa, Montserrat Andreu, Artemio Paya, Antoni Castells.   

Abstract

AIM: To evaluate changes in colorectal cancer (CRC) survival over the last 20 years.
METHODS: We compared two groups of consecutive CRC patients that were prospectively recruited: Group I included 1990 patients diagnosed between 1980 and 1994. Group II included 871 patients diagnosed in 2001.
RESULTS: The average follow up time was 21 mo (1-229) for Group I and 50 mo (1-73.4) for Group II. Overall median survival was significantly longer in Group II than in Group I (73 mo vs 25 mo, P < 0.001) and the difference was significant for all tumor stages. Post surgical mortality was 8% for Group Iand 2% for Group II (P < 0.001). Only 17% of GroupI patients received chemotherapy compared with 50% of Group II patients (P < 0.001).
CONCLUSION: Survival in colorectal cancer patients has doubled over the past 20 years. This increase seems to be partly due to the generalization in the administration of chemotherapy and to the decrease of post surgical mortality.

Entities:  

Mesh:

Year:  2010        PMID: 20143465      PMCID: PMC2825333          DOI: 10.3748/wjg.v16.i7.862

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

1.  Clinical studies with 5-fluorouracil.

Authors:  A R CURRERI; F J ANSFIELD; F A McIVER; H A WAISMAN; C HEIDELBERGER
Journal:  Cancer Res       Date:  1958-05       Impact factor: 12.701

2.  Two steps forward in the treatment of colorectal cancer.

Authors:  Robert J Mayer
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

3.  A population-based study of the incidence, mortality and outcomes in patients following surgery for colorectal cancer in Western Australia.

Authors:  J B Semmens; C Platell; T J Threlfall; C D Holman
Journal:  Aust N Z J Surg       Date:  2000-01

4.  Morbidity and mortality of colorectal carcinoma surgery differs by insurance status.

Authors:  Rachel Rapaport Kelz; Phyllis A Gimotty; Daniel Polsky; Sandra Norman; Douglas Fraker; Angela DeMichele
Journal:  Cancer       Date:  2004-11-15       Impact factor: 6.860

5.  [Mechanical sutures in surgery of cancer of the rectum (a personal contribution)].

Authors:  F Crucitti; L Sofo; G B Doglietto; R Bellantone; V Perri; F Zucchetti
Journal:  Chir Ital       Date:  1983-12

Review 6.  Adjuvant therapy of colorectal cancer. Why we still don't know.

Authors:  M Buyse; A Zeleniuch-Jacquotte; T C Chalmers
Journal:  JAMA       Date:  1988-06-24       Impact factor: 56.272

7.  [Surgical treatment of rectal cancer: comparison of anterior resection and abdominoperineal excision].

Authors:  L Boschi; F Lecce; F Bazzocchi; A Del Gaudio
Journal:  Minerva Chir       Date:  1995-10       Impact factor: 1.000

8.  Operative mortality following surgery for colorectal cancer.

Authors:  J L Canivet; P Damas; C Desaive; M Lamy
Journal:  Br J Surg       Date:  1989-07       Impact factor: 6.939

9.  Colorectal cancer surgery in the elderly: acceptable morbidity?

Authors:  Evan S Ong; Mohamed Alassas; Kelli Bullard Dunn; Ashwani Rajput
Journal:  Am J Surg       Date:  2008-03       Impact factor: 2.565

10.  New procedure for the treatment of colorectal neoplastic obstructions.

Authors:  E Tejero; A Mainar; L Fernández; R Tobío; M A De Gregorio
Journal:  Dis Colon Rectum       Date:  1994-11       Impact factor: 4.585

View more
  18 in total

1.  Expression of phosphorylated Stat5 predicts expression of cyclin D1 and correlates with poor prognosis of colonic adenocarcinoma.

Authors:  Yinling Mao; Zhiwei Li; Changjie Lou; Yanqiao Zhang
Journal:  Int J Colorectal Dis       Date:  2010-11-16       Impact factor: 2.571

2.  5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

Authors:  Rodrigo Jover; Thuy-Phuong Nguyen; Lucía Pérez-Carbonell; Pedro Zapater; Artemio Payá; Cristina Alenda; Estefanía Rojas; Joaquín Cubiella; Francesc Balaguer; Juan D Morillas; Juan Clofent; Luis Bujanda; Josep M Reñé; Xavier Bessa; Rosa M Xicola; David Nicolás-Pérez; Antoni Castells; Montserrat Andreu; Xavier Llor; C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-12-24       Impact factor: 22.682

3.  Population-based screening improves histopathological prognostic factors in colorectal cancer.

Authors:  Mónica Mengual-Ballester; Enrique Pellicer-Franco; Graciela Valero-Navarro; Victoriano Soria-Aledo; José Andrés García-Marín; José Luis Aguayo-Albasini
Journal:  Int J Colorectal Dis       Date:  2017-11-14       Impact factor: 2.571

4.  LSF expression and its prognostic implication in colorectal cancer.

Authors:  Hui Jiang; Jun Du; Jianqiang Jin; Xiaowei Qi; Yong Pu; Bojian Fei
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

5.  Colorectal Cancer Prevalence and Survival in Cuenca (Spain).

Authors:  Laura Valiente González; Ricardo de Miguel Ibáñez; Francisco Escribano Sotos
Journal:  J Gastrointest Cancer       Date:  2022-01-13

6.  Is CT-based body composition associated with long-term chemotherapy-induced peripheral neuropathy in colorectal cancer survivors?

Authors:  Debbie Smit; Floortje Mols; Cynthia S Bonhof; Martijn J L Bours; Gerard Vreugdenhil; Sandra Beijer
Journal:  Support Care Cancer       Date:  2022-04-13       Impact factor: 3.359

7.  High-throughput screening reveals higher synergistic effect of MEK inhibitor combinations in colon cancer spheroids.

Authors:  Evelina Folkesson; Barbara Niederdorfer; Vu To Nakstad; Liv Thommesen; Geir Klinkenberg; Astrid Lægreid; Åsmund Flobak
Journal:  Sci Rep       Date:  2020-07-14       Impact factor: 4.379

8.  The Effectiveness of Glutathione Redox Status as a Possible Tumor Marker in Colorectal Cancer.

Authors:  Delia Acevedo-León; Lidia Monzó-Beltrán; Segundo Ángel Gómez-Abril; Nuria Estañ-Capell; Natalia Camarasa-Lillo; Marisa Luisa Pérez-Ebri; Jorge Escandón-Álvarez; Eulalia Alonso-Iglesias; Marisa Luisa Santaolaria-Ayora; Araceli Carbonell-Moncho; Josep Ventura-Gayete; Luis Pla; Maria Carmen Martínez-Bisbal; Ramón Martínez-Máñez; Leticia Bagán-Debón; Aurora Viña-Almunia; M Amparo Martínez-Santamaría; María Ruiz-Luque; Jorge Alonso-Fernández; Celia Bañuls; Guillermo Sáez
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

9.  Evaluation of alpha 1-antitrypsin and the levels of mRNA expression of matrix metalloproteinase 7, urokinase type plasminogen activator receptor and COX-2 for the diagnosis of colorectal cancer.

Authors:  Luis Bujanda; Cristina Sarasqueta; Angel Cosme; Elizabeth Hijona; José M Enríquez-Navascués; Carlos Placer; Eloisa Villarreal; Marta Herreros-Villanueva; María D Giraldez; Meritxell Gironella; Francesc Balaguer; Antoni Castells
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

10.  Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection.

Authors:  Maria Teresa Rodia; Giampaolo Ugolini; Gabriella Mattei; Isacco Montroni; Davide Zattoni; Federico Ghignone; Giacomo Veronese; Giorgia Marisi; Mattia Lauriola; Pierluigi Strippoli; Rossella Solmi
Journal:  Oncotarget       Date:  2016-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.